LPCN 1144 RESULTS QUICK ANALYSIS


The figures provided by LIPOCINE  are based on intermediate MRI PDFF results.

All that results are on only 7 patients (over 9 included in the trial) no placebo arm.

 

Liver fat mesures using MRI PDFF


We can compare the relative fat reduction with  two other  trial already published using the same technique and endpoint .

vs placebo if placebo arm exist

MGL 3196    (MADRIGAL)   12wk          -36,3%  vs    -9,6%    

VK 2609   (VIKING)  12wk                       -59,7%     vs   -8,9% 

LPCN 1144  (LIPOCINE)    8wk               - 38%  vs no placebo    


We can also compare the absolute fat reduction with  two other  trial already published using the same technique and endpoint .

vs placebo if placebo arm exist

MGL 3196    (MADRIGAL)   12wk          -7.6%  vs    -1,6%    

VK 2609   (VIKING)  12wk                       -10,6%     vs   -0,9% 

LPCN 1144  (LIPOCINE)    8wk               - 7,6%  vs   no placebo 




We can see that LIPOCINE’s LPCN 1144 results at 8 weeks are close to MADRIGAL’s  MGL 3196  at 12 weeks but MADRIGAL results were obtained on 78 patients as LIPOCINE results  are only on 7 patients.  A complete phase 2 is neeeded to confirm LIPOCINE results.

Notice that mesuring liver fat via MRI PDFF is far from the golden standard (liver biopsy histology analysis) required in Phase 2 or Phase 3 in NASH ( as INTERCEPT, GILD and GENFIT Ph3 trials in course).



G Divry

Notice that I am neither a physician nor a biologist or financial analyst, my point of view is only that of an enlightened amateur, so it must be taken for what it is, a questionable point of view



WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016  - Contact and TERMS OF USE